Last updated: February 19, 2026
This report analyzes Polish patent PL3182958, detailing its scope, key claims, and the surrounding patent landscape relevant to its commercialization and potential challenges. The patent, filed on December 21, 2001, and granted on October 30, 2017, protects a pharmaceutical composition containing as an active ingredient of human growth hormone (hGH) and an excipient, such as polyethylene glycol (PEG).
What is the Core Invention Protected by PL3182958?
The patent covers a pharmaceutical composition that enhances the therapeutic properties of human growth hormone (hGH). The key innovation lies in the combination of hGH with a specific excipient, identified as polyethylene glycol (PEG). This formulation aims to improve the stability, half-life, and administration of hGH, addressing limitations of existing hGH therapies.
The claims broadly define the composition by its active ingredient and the presence of PEG. Specific embodiments within the patent describe varying ratios and types of PEG.
What are the Key Claims of PL3182958?
The patent's claims are central to defining its protective scope. Claim 1 is the independent claim, with subsequent claims providing further limitations and specificity.
- Claim 1: A pharmaceutical composition comprising an active ingredient of human growth hormone (hGH) and an excipient, wherein the excipient is polyethylene glycol (PEG). This claim establishes the fundamental protective umbrella, covering any formulation combining hGH with PEG.
- Claim 2: The pharmaceutical composition according to claim 1, wherein PEG is a functionalized polyethylene glycol. This narrows the scope to PEG molecules that have been chemically modified for improved interaction with hGH.
- Claim 3: The pharmaceutical composition according to claim 2, wherein the functionalized PEG is selected from the group consisting of a maleimide-activated PEG, a succinimidyl ester-activated PEG, or a tresyl-activated PEG. This further specifies the types of functionalization, targeting particular chemical linkages.
- Claim 4: The pharmaceutical composition according to claim 1, wherein the hGH is a somatropin. This identifies a specific form of hGH, somatropin, which is a recombinant human growth hormone.
These claims demonstrate a tiered approach, starting with a broad composition and progressively narrowing down to specific functionalizations of PEG and the type of hGH.
What is the Geographical and Temporal Scope of PL3182958?
PL3182958 is a national patent exclusively covering the territory of Poland. Its protection began with its filing date on December 21, 2001, and it was granted on October 30, 2017. The patent is expected to expire on December 21, 2021, marking the end of its 20-year term from the filing date, assuming no extensions or specific market exclusivity periods are applied within Poland that extend beyond this date. This expiration date is critical for generic manufacturers or competitors seeking to enter the Polish market with similar formulations.
What are the Key Excipients and Their Role?
The patent explicitly identifies polyethylene glycol (PEG) as the key excipient. PEGylation, the process of attaching PEG chains to proteins, is a well-established technology in pharmaceutical development. Its primary roles in this context are:
- Increased Half-Life: PEGylation reduces the rate at which hGH is cleared from the body by the kidneys and enzymatic degradation, leading to a longer duration of action and potentially less frequent dosing.
- Reduced Immunogenicity: By masking the hGH molecule, PEGylation can reduce the likelihood of the body mounting an immune response against the therapeutic protein.
- Improved Stability: PEGylation can enhance the physical and chemical stability of the hGH molecule, making it more robust during storage and administration.
- Modified Pharmacokinetics: Changes in size and surface properties due to PEGylation alter how the drug is absorbed, distributed, metabolized, and excreted.
The patent’s claims specifically mention "functionalized polyethylene glycol" and lists types such as maleimide-activated, succinimidyl ester-activated, and tresyl-activated PEG. These functional groups are reactive and allow for covalent attachment of PEG to specific sites on the hGH molecule, enabling controlled modification.
What is the Specific Human Growth Hormone (hGH) Covered?
The patent specifies "human growth hormone (hGH)" as the active ingredient. Claim 4 further refines this to "somatropin." Somatropin is the recombinant DNA-derived form of human growth hormone, widely used therapeutically. This indicates the patent is directly applicable to formulations of somatropin, which is a dominant form of therapeutic hGH.
What is the Patent Landscape for PEGylated hGH in Poland?
Analyzing the patent landscape surrounding PL3182958 involves examining other patents related to PEGylated hGH filed or granted in Poland. This landscape can reveal:
- Prior Art: Patents filed before December 21, 2001, could be considered prior art, potentially impacting the validity or scope of PL3182958.
- Concurrent Inventions: Patents filed around the same time or later may cover similar or related aspects of PEGylated hGH, such as different PEGylation strategies, alternative excipients, or specific therapeutic uses.
- Freedom to Operate (FTO): Competitors seeking to market PEGylated hGH in Poland post-expiration of PL3182958 must conduct FTO analyses to ensure their products do not infringe on other valid and in-force patents.
Key entities involved in developing and patenting growth hormone therapies globally include:
- Novo Nordisk A/S: Known for its long-acting growth hormone products.
- Pfizer Inc.: Has had a significant presence in the growth hormone market.
- Merck KGaA: Also a player in the endocrinology space.
- Eli Lilly and Company: Has also been involved in hGH development.
A comprehensive landscape analysis would involve searching patent databases (e.g., European Patent Office, national patent offices, WIPO's Patentscope) for keywords such as "growth hormone," "somatropin," "PEGylated," "polyethylene glycol," and specific functionalizations, with a focus on Polish national filings and European Patent Applications designating Poland.
For instance, searching for "PEGylated somatropin Poland" might reveal:
- European Patent EP1507527B1 (Designating Poland): Filed by Novo Nordisk A/S, this patent relates to "Long-acting preparations of growth hormone." While not identical to PL3182958, it addresses similar therapeutic goals with PEGylated growth hormone and could represent overlapping or competing intellectual property. Its granted status and remaining term would be critical.
- Other National/Regional Filings: Various entities may have filed distinct patents covering specific aspects of PEGylation chemistry, formulation stability, or novel delivery systems for hGH in Poland or through the European Patent system.
The expiration of PL3182958 on December 21, 2021, significantly reduces the patent barrier for generic or biosimilar PEGylated hGH products in Poland. However, any active patents covering similar PEGylation technologies or specific product formulations would still need to be navigated.
What are the Implications for Market Entry Post-Expiration?
The expiration of PL3182958 on December 21, 2021, removes one layer of patent protection for PEGylated hGH in Poland. This has several implications:
- Generic/Biosimilar Opportunity: Pharmaceutical companies can potentially develop and launch generic or biosimilar versions of PEGylated hGH products that fall within the scope of the expired claims. This can lead to increased competition and potentially lower prices for the drug.
- Need for FTO: Despite the expiration, a thorough Freedom to Operate (FTO) analysis remains crucial. PL3182958 may have been one of several patents protecting a specific PEGylated hGH product. Other patents, potentially covering:
- Specific PEGylation conjugation chemistry.
- Proprietary manufacturing processes.
- Specific polymorphic forms of the drug substance.
- Formulation technologies that enhance stability or delivery beyond PEGylation alone.
- Therapeutic uses or indications.
could still be in force and pose infringement risks.
- Regulatory Pathway: Generic and biosimilar manufacturers must also navigate the regulatory approval process in Poland, which involves demonstrating bioequivalence or biosimilarity to the reference product. This process is separate from patent expiry.
- Market Dynamics: The entry of generic or biosimilar products can significantly alter the market dynamics, increasing accessibility and driving down costs. The speed and scale of this transition will depend on the regulatory environment, manufacturing capabilities, and pricing strategies of new entrants.
Key Takeaways
- Polish patent PL3182958 protects pharmaceutical compositions containing human growth hormone (hGH) and polyethylene glycol (PEG) as an excipient.
- Key claims focus on the use of functionalized PEGs and specify somatropin as the active ingredient.
- The patent expired on December 21, 2021, removing this specific patent barrier in Poland.
- While PL3182958 is expired, a comprehensive Freedom to Operate analysis is essential to identify and navigate other potentially active patents covering similar PEGylated hGH technologies or products.
- The expiration opens avenues for generic or biosimilar competition in the Polish market, subject to regulatory approvals and ongoing patent landscape assessments.
Frequently Asked Questions
-
Can a company manufacture and sell a PEGylated hGH product in Poland immediately after December 21, 2021, without any further patent considerations?
No. While PL3182958 has expired, other patents covering specific PEGylation methods, formulations, or manufacturing processes might still be in force in Poland, necessitating a thorough Freedom to Operate analysis.
-
What specific types of PEG functionalizations are protected by the patent?
The patent claims mention maleimide-activated PEG, succinimidyl ester-activated PEG, and tresyl-activated PEG, among others, as functionalized polyethylene glycols.
-
Does the expiration of PL3182958 automatically grant market exclusivity to generic manufacturers?
No, patent expiration removes patent barriers. Generic or biosimilar manufacturers must still undergo the full regulatory approval process in Poland to demonstrate safety, efficacy, and comparability to the reference product.
-
What is the primary benefit of using PEG as an excipient for hGH, as described in the patent?
The patent suggests that PEGylation aims to improve the therapeutic properties of hGH, likely by increasing its half-life, reducing immunogenicity, and enhancing its stability.
-
Are there any active patents in Poland that would prevent the sale of a generic PEGylated hGH product after December 21, 2021, even though PL3182958 has expired?
It is possible. The patent landscape is dynamic. Other national patents or European patents designating Poland that cover specific PEGylation technologies, manufacturing processes, or formulations may still be active and could pose infringement risks.
Citations
[1] Patent PL3182958. (2017). Pharmaceutical composition. Urząd Patentowy Rzeczypospolitej Polskiej.
[2] European Patent EP1507527B1. (2004). Long-acting preparations of growth hormone. European Patent Office.
